The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis

被引：0
|
作者：
Seong-Jang Kim
Kyoungjune Pak
Phillip J. Koo
Jennifer J. Kwak
Samuel Chang
机构：
[1] Pusan National University Hospital,Department of Nuclear Medicine and Biomedical Research Institute
[2] University of Colorado School of Medicine,Department of Radiology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2015年 / 42卷
关键词：
Neuroendocrine tumour; Lutetium; Radionuclide therapy; Peptide receptor therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1964 / 1970
页数：6
相关论文
共 50 条
  • [1] The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis
    Kim, Seong-Jang
    Pak, Kyoungjune
    Koo, Phillip J.
    Kwak, Jennifer J.
    Chang, Samuel
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (13) : 1964 - 1970
  • [2] Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors A Meta-analysis
    Saravana-Bawan, Bianka
    Bajwa, Amandeep
    Paterson, John
    McEwan, Alexander J. B.
    McMullen, Todd P. W.
    [J]. CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 719 - 727
  • [3] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Zhang, Jie
    Song, Qi
    Cai, Liang
    Xie, Ying
    Chen, Yue
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) : 1533 - 1543
  • [4] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Jie Zhang
    Qi Song
    Liang Cai
    Ying Xie
    Yue Chen
    [J]. Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1533 - 1543
  • [5] Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)
    Ameya D. Puranik
    Harshad R. Kulkarni
    Aviral Singh
    Richard P. Baum
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 1223 - 1230
  • [6] Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)
    Puranik, Ameya D.
    Kulkarni, Harshad R.
    Singh, Aviral
    Baum, Richard P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (08) : 1223 - 1230
  • [7] Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours
    Bodei, L.
    Cremonesi, M.
    Grana, C.
    Bartolomei, M.
    Baio, S.
    Bufi, G.
    Fiorenza, M.
    Obenaus, E.
    Paganelli, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S214 - S214
  • [8] Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
    Sabet, Amir
    Dautzenberg, Kristina
    Haslerud, Torjan
    Aouf, Anas
    Sabet, Amin
    Simon, Birgit
    Mayer, Karin
    Biersack, Hans-Juergen
    Ezziddin, Samer
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (08) : 1238 - 1246
  • [9] Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
    Amir Sabet
    Kristina Dautzenberg
    Torjan Haslerud
    Anas Aouf
    Amin Sabet
    Birgit Simon
    Karin Mayer
    Hans-Jürgen Biersack
    Samer Ezziddin
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 1238 - 1246
  • [10] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
    Del Prete, Michela
    Buteau, Francois-Alexandre
    Beauregard, Jean-Mathieu
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) : 1490 - 1500
12345